Home / Market News / $IQV
benzinga Corporate Catalyst Impact 65/100 ● positive

IQVIA Expands Partnership Veeva Systems On Enterprise Standard Applications That Will Be Used Across IQVIA Clinical Development Studies

Oct 13, 2026, 11:15 AM UTC · Primary ticker $IQV

IQVIA has expanded its partnership with Veeva Systems, adopting several Veeva clinical solutions as enterprise-standard applications for its clinical development studies. This move aims to enhance trial speed, efficiency, and decision-making, potentially benefiting both companies and their clients in the life sciences sector.

IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard applications for its clinical development studies. This builds on their existing EDC partnership, signifying a deeper integration of Veeva's technology into IQVIA's core operations. For IQVIA, this means standardizing on a leading platform to improve clinical trial efficiency and speed, potentially leading to cost savings and faster drug development for its clients. For Veeva, it represents a significant win, securing a major contract research organization (CRO) as an enterprise-wide customer, further solidifying its market leadership in clinical trial software. This is a positive development for both companies, suggesting long-term operational efficiencies for IQV and increased revenue and market penetration for VEEV. Traders should see this as a positive signal for both, with IQV potentially gaining efficiency and VEEV securing a larger recurring revenue stream.

$IQV positive Expanded partnership for core operations
$VEEV positive Increased adoption of enterprise solutions
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.